Hypertension jab is just five years away

American Heart Association Conference HRT may be cardioprotective, promising results for hypertension jab, disturbed sleep link to statin and ARBs 'best choice in chronic kidney disease'.

An injection to control hypertension could be available within five to 10 years, Swiss scientists have claimed.

Preliminary findings indicate that an antibody vaccine, that binds to angiotensin II so it is unable to activate angiotensin receptors, has efficacy and is tolerable. It is the first vaccine shown to reduce BP, according to the researchers.

The study included 72 people with mild-to-moderate hypertension who were injected with 100(mu)g or 300(mu)g of the vaccine CYT006-AngQb, or placebo.

Injections of the vaccine developed by company Cytos Biotechnology in Zurich were given at baseline, and at four and 12 weeks later.

Patients given the vaccine showed a strong response against angiotensin II, especially when given the stronger dose, researchers told delegates at the American Heart Association scientific sessions in Orlando, Florida.

Evaluation of 24-hour BP at 14 weeks showed those given 300(mu)g of vaccine had a 5.6mmHg reduction in systolic BP and a 2.8mmHg reduction in diastolic BP.

These effects were more pronounced between 5am and 8am, when hypertensive patients are at most risk of MI, said lead researcher Professor Juerg Nussberger, from the University Hospital of the Canton of Vaud in Lausanne, Switzerland.

rachel.liddle@haymarket.com

AHA scientific sessions 4-7 November 2007, Orlando, Florida

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Vaccination tracker

UK COVID-19 vaccination programme tracker

GPs across the UK have led the largest-ever NHS vaccination programme in response...

RCGP chair Professor Martin Marshall

Hand PCNs control of primary care infrastructure funding, says RCGP

CCG funding for primary care infrastructure should be handed to PCNs when the bodies...

Professor Martin Marshall and Talking General Practice logo

Podcast: RCGP chair Professor Martin Marshall

Talking General Practice speaks to RCGP chair Professor Martin Marshall.

Dr Chaand Nagpaul

In-house review not enough to stop 'unjust' GMC referrals, warns BMA

Doctors' leaders have repeated calls for a full independent review of the GMC referral...

Coronavirus

How widespread is long COVID in the UK?

Millions of people in the UK are living with long COVID. GPonline looks at the data...

COVID-19 vaccination sign

GP contract for autumn COVID-19 booster campaign due shortly

GP practices in England will be invited shortly to sign up for the COVID-19 autumn...